On June 17, 2025, MIRA Pharmaceuticals announced its lead drug candidate, Ketamir-2, was accepted for publication in a scientific journal, highlighting its potential as a new treatment for neuropathic pain with unique properties and low side effects. Additionally, the company confirmed progress on its acquisition of SKNY Pharmaceuticals and upcoming clinical trials.